RINGSIDE Trial Results and Clinical Implications

Dr. Basu Mallick highlights the impressive efficacy demonstrated in the RINGSIDE phase 3 trial of varagesestat, particularly the hazard ratio of 0.16 representing an 84% reduction in progression risk. Although response depth appeared notable, she emphasizes that pain relief represents the most clinically meaningful endpoint for patients with benign locally aggressive tumors.

The trial demonstrated statistically significant and clinically meaningful pain improvement within 12 weeks, with curves showing steep improvement as early as 4 weeks, providing rapid symptomatic benefit to patients. This rapid onset of pain relief often occurs before radiographic tumor shrinkage, representing a characteristic feature of gamma-secretase inhibitor class effects.

Despite 80% of patients requiring dose reductions, efficacy was maintained even at reduced doses, emphasizing the importance of dose management rather than treatment discontinuation. The once-daily dosing schedule represents a practical advantage for chronic administration, potentially improving compliance compared to twice-daily regimens.

Dr. Bui addresses the clinical significance of tumor volume reduction, noting that although waterfall plots typically favor deeper responses, the benign nature of desmoid tumors makes functional improvement more relevant than absolute shrinkage percentages. Pain relief, functional status improvement, and opioid reduction represent more meaningful endpoints than specific response rates.

The side effect profile remained consistent with the gamma-secretase inhibitor class, including diarrhea, rash, and fatigue, without unexpected toxicities. However, the high rate of dose reductions raises questions about optimal starting doses and potential for dose escalation strategies in future clinical practice.